 Home > Active Ingredient News > Blood System > J Thromb Haemost: Analysis of risk factors for bleeding in patients with hemophilia A and B

J Thromb Haemost: Analysis of risk factors for bleeding in patients with hemophilia A and B

 Last Update: 2022-05-15
 Source: Internet
 Author: User

Tags

coagulation factor deficiency

sasol north america

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The basis of hemophilia treatment is the treatment of coagulation factor deficiencies

The aim of this study was to systematically review the literature on risk assessment models (RAMs) and risk factors for regular bleeding prevention with PWH

The purpose of this study was to systematically review the literature on risk assessment models (RAMs) and risk factors for regular bleeding prevention with PWH

We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews from inception to August 2019

Of the 1843 search results, 10 studies met the inclusion criteria

Thus, the results of this study suggest that plasma coagulation factor levels and bleeding history should be used as the basis for derivation analysis when constructing a PWH bleeding RAM, and the role of other risk factors including antithrombotic therapy and obesity should be explored

When constructing a PWH bleeding RAM, plasma coagulation factor levels and bleeding history should be used as the basis for derivation analysis, and the role of other risk factors including antithrombotic therapy and obesity should be explored

Original source: Federico Germini.

Original source: Federico Germini.
et al.
Risk factors for bleeding in people living with Hemophilia A and B treated with regular prophylaxis: a systematic review of the literature .
Journal of Thrombosis and Haemostasis.
2022.
https://onlinelibrary.
wiley.
com /doi/epdf/10.
1111/jth.
15723.
Risk factors for bleeding in people living with Hemophilia A and B treated with regular prophylaxis: a systematic review of the literatureLeave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

SULODEXIDE 99% Almost White Powder Dideu-01112 Dideu

CAS No.: 57821-29-1

Pharmacy Grade

$61.76/G EXW

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide

CAS No.: 204656-20-2

Pharmacy Grade

$30.00/G FOB

Heparin sodium 9041-08-1 vials safe delivery

CAS No.: 9041-08-1

Pharmacy Grade

$1/G EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.